HARBOUR BIOMED

和鉑醫藥控股有限公司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT ENTERING INTO EVALUATION AND LICENSE AGREEMENT WITH UMOJA BIOPHARMA

This announcement is made by HBM Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that Nona Biosciences (Suzhou) Co., Ltd ("**Nona Biosciences**"), a subsidiary wholly-owned by the Company, and Umoja Biopharma, Inc. ("**Umoja Biopharma**") have entered into an evaluation and license agreement (the "**Agreement**"), which aims to create multiple *in vivo* CAR-T cell products by combining Nona Biosciences' proprietary HCAb Harbour Mice® and NonaCarFx™ platforms with Umoja Biopharma's VivoVec™ platform. The Agreement represents an expansion of the strategic collaboration established between the two companies in September 2024.

Under the terms of the Agreement, Nona Biosciences is eligible to receive an upfront payment, potential option exercise fees and milestone payments tied to the discovery and development of specific programs in the collaboration. Umoja Biopharma will be responsible for all further product development and commercialization.

About Umoja Biopharma

Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop *in vivo* cell therapies that improve the reach, effectiveness, and access of CAR-T cell therapies in both oncology and autoimmunity. Umoja Biopharma's VivoVec™ *in vivo* gene delivery technology empowers a patient's own immune system to fight disease. Enabling its core technology is the company's state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. Umoja Biopharma believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives.

Cautionary Statement

We cannot guarantee that we or our collaboration partners will be able to successfully develop or ultimately market any of the product candidates referenced in this announcement. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 5 November 2025

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.